Conditioning Regimens for Bone Marrow and Peripheral Blood Stem Cell Transplantation

  • Angelo M. Carella
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 37)


Patients with acute leukemias or CML still have a poor prognosis when treated with standard dose chemotherapy alone. In view of this situation, myeloablative chemotherapy with bone marrow transplantation (BMT) or, more recently, autologous peripheral blood stem cell transplantation (ASCT), has become more and more an established methodology in the treatment of hematological neoplasias as well as some solid tumor types [Sheridan 1992, Brugger 1993].


Chronic Myeloid Leukemia Chronic Myelogenous Leukemia Total Body Irradiation Peripheral Blood Stem Cell Transplantation Peripheral Blood Progenitor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aversa F, Terenzi A, Carrotti A, Martelli MP, Latini P, Gambelunghe C, Martelli MF. Addition of thiotepa improves results in T-Cell depleted bone marrow transplant for advanced leukemia. Blood ASH 1993; Vol. 82 u. 10, suppl. 1Google Scholar
  2. 2.
    Berman E, Heller G, Santorsa JA, McKenzie S, Gee T et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosin arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666–1674.PubMedGoogle Scholar
  3. 3.
    Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267–3273.PubMedGoogle Scholar
  4. 4.
    Biggs JC, Szer J, Czilley P, Atkinson K, Downs K, Dodds A, Concannon AJ, Avalos B, Tutschka P, Kapoor N, Bzodsky I, Topolsky D, Bulsva SI, Copelan EA. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy 2. Blood 1992; 80: 1352–1357.PubMedGoogle Scholar
  5. 5.
    Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, Milpied N, Attal M, Michallet M, Ifrah N, Kuentz M, Dauriac C, Bordigoni P, Gratecos N, Guilhot F, Guyotat D, Gouvernet J, Gluckman E. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation a preparative regimen. Blood 1991; 79: 2578–2582.Google Scholar
  6. 6.
    Blume KG, Forman SJ, O’Donnell MR, Doroshow JH, Krance RA, Nademanee AP, Snyder DS, Schmidt GM, Fahey JL, Metter GE, Hill LR, Findley DO, Sniecinski IJ. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69: 1015–1020.PubMedGoogle Scholar
  7. 7.
    Brugger W, Bross K, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636.PubMedGoogle Scholar
  8. 8.
    Brugger W, Birken R, Bertz H, Hecht T, Pressler K, Frisch J, Schulz G, Mertelsmann R, Kanz L. Peripheral blood progenitor cells mobilized by chemotherapy plus G-CSF accelerate both neutrophil and platelet recovery after high-dose VP-16, ifosfamide and cisplatin. Br J Hematol 1994; 84: 402.CrossRefGoogle Scholar
  9. 9.
    Buckner. Blood in press. 1994.Google Scholar
  10. 10.
    Capranico G, Riva A, Tinelli S, Dasdia T, Zunino F. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei. Cancer Res 1987; 47: 3752–3756.PubMedGoogle Scholar
  11. 11.
    Carella AM, Podesta M, Frassoni F, Raffo MR, Pollicardo N. Collection of “normal” blood repopulating cells during early hemopietic recovery after intensive conventional chemotherapy in CML. Bone marrow Transplantation 1993; 12: 267–271.PubMedGoogle Scholar
  12. 12.
    Carella AM, Podesta M, Pollicardo N, Pungolino E, Raffo MR, Ferrero MR, Belgumaschi G, Rost V, Cazzola M, Saglio G, Frassoni F. Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/D2− cells with high proliferative potential which sustain Ph-negative polyclonal hematopotesis. Leukemia 1994; 1: 212–213.Google Scholar
  13. 13.
    Carella AM, Pollicardo N, Raffo MR, Podesta M, Carlier P, Valbonesi M, Lercari G, Vitale V, Gallamini A. Intensive conventional chemotherapy can lead to a precocious overshoot of cytogenetically normal blood stem cells in chronic myeloid leukemia and acute lymphoblastic leukemia. Leukemia 1992; 6(suppl. 4): 120–123.PubMedGoogle Scholar
  14. 14.
    Carella AM, Gaozza E, Raffo MR, Carlier P, Frassoni F, Valbonesi M, Lercari G, Sessarego M, Defferrari R, Guerrasio A. Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A. Leukemia 1991; 6: 517–521.Google Scholar
  15. 15.
    Carella AM, Berman E, Maraone MP, Ganzina F. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Haematologica 1990; 75: 159–169.PubMedGoogle Scholar
  16. 16.
    Casazza AM, Bertazolli G, Pratesi G. Antileukemic activity and cardiac toxicity of 4-demethoxy-daunorubicin. Proc Am Ass Cancer Res 1979; 20: 16.Google Scholar
  17. 17.
    Clift RA, Buckner CD, Appelbaum FA, Bryant E, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill RS, McDonald GB, Martin P, Meyers J, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, Thomas ED. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase. A randomized trial of two irradiation regimens. Blood 1991; 77: 1660–1665.PubMedGoogle Scholar
  18. 18.
    Coccia PF, Stranjord SE, Warkentin PI, Cheung NV, Gordon EM, Novak LJ, Shina DC, Herzig RH. High-dose cytosine arabinoside and fractionated total body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood 1988; 71: 888–893.PubMedGoogle Scholar
  19. 19.
    Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves A. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308: 1493–1498.PubMedCrossRefGoogle Scholar
  20. 20.
    Geller RB, Saral R, Piantadosi S, Zahurak M, Vogelsang GB, Wingard JR, Ambinder RF, Beschorner WB, Braine HG, Burns WH, Hess AD, jones RJ, May WS, Rowley SD, Wagner JE, Yeager AM, Santos GW. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 1989; 73: 2209–2218.PubMedGoogle Scholar
  21. 21.
    Gieseler F, Clark M, Wilms K. Cellular uptake of anthracyclines, intracellular distribution, DNA binding and topoisomerase II activity. Determinants for hematopoietic cell sensitivity in chemotherapy. Ann Hematol 1994; 68(suppl. 1): A24, abstract 95.Google Scholar
  22. 22.
    Goldman JM. Options for the management of chronic myeloid leukemia 1990. Leukemia and Lymphoma 1990; 3: 159–164.CrossRefGoogle Scholar
  23. 23.
    Juttner CA, To LB, Haylock DN, Branford A, Kimber RJ. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukemia produce prompt but incomplete hematopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Hematol 1985; 61: 739–744CrossRefGoogle Scholar
  24. 24.
    Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211–213.PubMedGoogle Scholar
  25. 25.
    Körbling M, Dörken B, Ho AD. Autologous transplantation of blood-derived hematopoietic stem cells after myeloablative therapy in a patient with Burkitt’s lymphoma. Blood 1986; 72: 529–534.Google Scholar
  26. 26.
    Müller MR, Lennartz K, Boogen C, Nowrousian MR, Rajewski MF, Seeber S. Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression. Ann Hematol 1992; 65: 206–212.PubMedCrossRefGoogle Scholar
  27. 27.
    Plumbridge TW, Brown JR. Studies on the mode of interaction of 4′-epi-adriamycin and 4-demethoxy-daunomycin with DNA. Biochem Pharmacol 1978; 27: 1881–1882.PubMedCrossRefGoogle Scholar
  28. 28.
    Santos GW. Marrow transplantation in acute non-lymphocytic leukemia. Blood 1989; 74: 901–908.PubMedGoogle Scholar
  29. 29.
    Sayer HG, Beelen DW, Quabeck K, Mohnke M, Oidtmann M, Schaefer UW. Comparison of high-dose busulfan and total body irradiation prior to allogeneic bone marrow transplantation. In: Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J (eds) Acute Leukemias IV. Springer, Berlin Heidelberg New York, 1994, pp. 689–693.CrossRefGoogle Scholar
  30. 30.
    Sessarego M, Fugazza G, Frassoni F, Defferrari R, Bruzzone R, Carella AM. Cytogenetic analysis of hematopoietic peripheral blood cells collected by leukapheresis after intensive chemotherapy in advanced phase Philadelphia-positive chronic myelogenous leukemia. Leukemia 1992; 6: 715–719.PubMedGoogle Scholar
  31. 31.
    Sheridan WP, Begley CG, Juttner CA. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–644.PubMedCrossRefGoogle Scholar
  32. 32.
    Singer JW, Arlin ZA, Najfeld V, Adamson JW, Kempin SJ, Clarkson BD, Fialkow PJ. Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia following a chemotherapy induced loss of the Ph1+ chromosome. Blood 1980; 56: 356–360.PubMedGoogle Scholar
  33. 33.
    Tutschka PJ, Copelan EA, Kapoor N. Replacing total body irradiation with busulfan as conditioning of patients with leukemia for allogeneic marrow transplantation. Transplant Proc 1989; 21: 2952–2954.PubMedGoogle Scholar
  34. 34.
    Wiernik PH. New agents in the treatment of acute myeloid leukemia. Sem Hematol 1991; 28(suppl. 4): 95–98.Google Scholar
  35. 35.
    Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J, Deeg HJ, Doney K, Thomas D, Storb R, Thomas ED. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784–789.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Angelo M. Carella
    • 1
  1. 1.Department of Hematology and Bone Marrow Transplantation UnitOspedale San MartinoGenovaItaly

Personalised recommendations